T cells play a central role in immune responses to cancer.37 Currently in clinical practice, PD-1/PD-L1 status and CD8 + TILs have been suggested as appropriate measurements to predict different clinical outcomes and inform immunotherapeutic strategies.38–40. The gene discussed is CD8A; the disease is cancer.